The available evidence suggests that EZH2 has oncogenic properties, and its overexpression in prostate and breast cancers promotes tumorigenesis, invasiveness and metastasis (Varambally et al., 2002; Kleer et al., 2003). Here, EZH2 is linked to breast carcinoma.